Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024


Option and Evaluation Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2024

Publication date
March 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition
4 - fully revised and updated

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.

Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024.

The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals.

Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.


Key benefits

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse option and evaluation deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Option and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in option and evaluation dealmaking in the biopharma industry
  • Overview of option and evaluation deal structure
  • Directory of option and evaluation deal records covering pharmaceutical and biotechnology
  • The leading option and evaluation deals by value
  • Most active option and evaluation dealmakers
  • The leading option and evaluation partnering resources


In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type


Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse option and evaluation deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in option and evaluation dealmaking

2.1. Introduction

2.2. Definition of option and evaluation deal

2.3. Trends in option and evaluation deals since 2016

2.3.1. Option and evaluation dealmaking by year, 2016-2024

2.3.2. Option and evaluation dealmaking by phase of development, 2016-2024

2.3.3. Option and evaluation dealmaking by industry sector, 2016-2024

2.3.4. Option and evaluation dealmaking by therapy area, 2016-2024

2.3.5. Option and evaluation dealmaking by technology type, 2016-2024

2.3.6. Option and evaluation dealmaking by most active company, 2016-2024

2.4. Reasons for entering into option and evaluation partnering deals

2.5. The future of option and evaluation deals


Chapter 3 – Overview of option and evaluation deal structure

3.1. Introduction

3.2. Option and evaluation agreement structure


Chapter 4 – Leading option and evaluation deals

4.1. Introduction

4.2. Top option and evaluation deals by value


Chapter 5 – Top 25 most active option and evaluation dealmakers

5.1. Introduction

5.2. Top 25 most active option and evaluation dealmakers


Chapter 6 – option and evaluation deals including contracts directory

6.1. Introduction

6.2. Option and evaluation deals with contracts 2016-2024


Deal directory

Deal directory – option and evaluation dealmaking by companies A-Z

Deal directory – option and evaluation dealmaking by therapy area

Deal directory – option and evaluation dealmaking by technology type


About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering



Figure 1: Definition of option and evaluation

Figure 2: Trends in option and evaluation deal announcements, 2016-2024

Figure 3: Option and evaluation deals signed at each phase of development, 2016-2024

Figure 4: Option and evaluation deals by industry sector, 2016-2024

Figure 5: Option and evaluation deals by therapy area, 2016-2024

Figure 6: Option and evaluation deals by technology type, 2016-2024

Figure 7: Top 25 most active option and evaluation dealmakers, 2016-2024

Figure 8: Top option and evaluation deals by value, 2016-2024

Figure 9: Most active option and evaluation dealmakers, 2016-2024

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2cureX, 2seventy bio, 3D Medicines, 3SBio, 3T Biosciences, 4D Molecular Therapeutics, 4D Pharma, 9 Meters Biopharma, 48Hour Discovery, A2 Biotherapeutics, A2A Pharmaceuticals, Aarvik Therapeutics, Abbisko Therapeutics, Abbott Laboratories, Abbvie, AbCellera Biologics, AbClon, Abera Bioscience, Abide Therapeutics, Abingworth Management, Ablynx, AbSci, Acceleron Pharma, Accent Therapeutics, Acelyrin, Acepodia, Acer Therapeutics, Ache, Achilles Therapeutics, AC Immune, Acucela, Acuitas Therapeutics, Adagene, Adapsyn Bioscience, Adaptimmune, Adaptive Biotechnologies, Adaptive Phage Therapeutics, AdaptVac, Adcendo, ADC Therapeutics, Addario Lung Cancer Medical Institute, Adhera Therapeutics, Adicet Bio, Adimab, AdoRx Therapeutics, ADT Pharmaceuticals, Aduro BioTech, Advaite, Advanced Accelerator Applications, Advanced Proteome Therapeutics, Aegea Biotechnologies, Aelis Pharma, Aequus Pharmaceuticals, Aerpio Pharmaceuticals, Aevi Genomic Medicine, Aexon Labs, Affibody, Affilogic, Affini-T Therapeutics, Affinia Therapeutics, Agenus Bio, AgeX Therapeutics, AgNovos Healthcare, AgonOx, AIkido Pharma, Aileron Therapeutics, AIMM Therapeutics, Ainos, Aitia, Ajinomoto, AJU Pharma, Akcea Therapeutics, Akebia Therapeutics, Akero Therapeutics, Akkadeas Pharma, Albumedix, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, Alivio Therapeutics, Allarity Therapeutics, Allegro Ophthalmics, Allergan, Allergan Aesthetics, Alligator Bioscience, Allist Pharma, Allogene Therapeutics, Allorion Therapeutics, Almirall, Alnylam Pharmaceuticals, Alphageneron Pharmaceuticals, Alpine Immune Sciences, ALRISE Biosystems, Altamira Therapeutics, Altavant Sciences, Alteogen, Alternavida, Altos Group, Amagma Therapeutics, Amarantus BioSciences, Amasa Therapeutics, Amathus Therapeutics, Ambys Medicines, Amerimmune, Amgen, AmMax Bio, Amolyt Pharma, Amorsa Therapeutics, Anaeropharma, ANANDA Scientific, Anchiano Therapeutics, Anergis, AnGes MG, Anima Biotech, Anokion, Antares Pharma, Antengene, Apceth, Apellis Pharmaceuticals, Apexigen, Applied DNA Sciences, Apricity Health, Aptevo Therapeutics, Aptorum Group, Aptose Biosciences, APT Therapeutics, Aqemia, Aqilion, Arbutus, ARCA Biopharma, Arcellx, Arcturus Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics, Ardelyx, Arecor, Arena Pharmaceuticals, Ares Genetics, argenx, Aridis Pharmaceuticals, Aristea Therapeutics, Arkuda Therapeutics, Arovella Therapeutics, ArQule, Arrakis Therapeutics, Array Biopharma, ArriVent Biopharma, Arrowhead Pharmaceuticals, Arsenal Biosciences, Artelo Biosciences, Artios Pharma, Artisan Bio, Artiva Biotherapeutics, Artizan Biosciences, Aruvant Sciences, Asahi Kasei, Ascenion, Ascentage Pharma, ASC Therapeutics, Asep Medical, Asieris Pharmaceuticals, ASKA Pharmaceuticals, Asklepios Biopharmaceutical, Aslan Pharma, Assembly Biosciences, Astellas Institute for Regenerative Medicine, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, ATAI Life Sciences, Atara Biotherapeutics, Ateria Health, Athebio, Atlab Pharma, Atomwise, Atossa Therapeutics, Atreca, Attralus, AuraVax Therapeutics, Aurigene Discovery Technologies, Aurinia Pharmaceuticals, Aurora Cannabis, Autifony Therapeutics, Autolus, Avacta, Avenzo Therapeutics, AVEO Oncology, Avista Pharma Solutions, Avita Therapeutics, Avrobio, Aytu BioPharma, Aziyo Biologics, Azura Ophthalmics, Barr Laboratories, BASE10 Genetics, Basilea Pharmaceutica, Battelle, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer CropScience, Baylor College of Medicine, Baylor Scott and White Research Institute, Beacon Discovery, Beam Therapeutics, BeiGene, Belharra Therapeutics, Bellicum Pharmaceuticals, Beta Therapeutics, BGN Technologies, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bintai Kinden, Bio-Path, Bio-Techne, Bio-Thera Solutions, BioAge Labs, BioArctic Neuroscience, biOasis Technologies, BioAtla, BioCardia, Biocept, BioCorRx, Biocytogen, Biodesix, Biodextris, Biogen, Biohaven Pharmaceuticals, BioInvent, Biolojic Design, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, BioMotiv, BiomX, BiondVax, Bioniz Therapeutics, BioNova Pharmaceuticals, BioNTech, BioRap Technologies, Biorchestra, BioSense Global, Biotheus, Bit Bio, BlinkBio, Bliss Biopharmaceutical, Bloom Science, Bluebird Bio, Blueprint Medicines, BlueRock Therapeutics, Boehringer Ingelheim, Bohai Biomedical, Bold Therapeutics, Bolt Biotherapeutics, Bone Biologics, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Braeburn Pharmaceuticals, Brammer Bio, Breakthrough Diagnostics, BriaCell Therapeutics, BridgeBio Pharma, BrightPath Biotherapeutics, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Broad Institute, Bruno Farmaceutici, Byondis, C4 Therapeutics, C4X Discovery, Cabaletta Bio, Caelum Biosciences, Calder Biosciences, Califia Pharma, California Institute for Biomedical Research, Calithera Biosciences, Camarus, CANbridge Pharmaceuticals, Cancer Genetics, Cancer Prevention Pharmaceuticals, Cancer Research UK, Cannassure Therapeutics, Capsida Biotherapeutics, Captor Therapeutics, Caraway Therapeutics, Cardiff Oncology, Cardiovascular Systems, Caribou Biosciences, Caris Life Sciences, Carisma Therapeutics, Carmine Therapeutics, Carnegie Mellon University, Case Western Reserve University, Catalent, Catalyst Pharmaceuticals, CBD Solutions, Celcuity, Celgene, Cellares, Cellectar Biosciences, Cellect Biotechnology, Cellectis, Cellenkos, Cell Medica, Celltech, Celltrion, Cellular Biomedicine, Celmatix, Celsius Therapeutics, Celularity, Celyad, Censa Pharmaceuticals, Centre For The Commercialization Of Antibodies And Biologics, Century Therapeutics, Cerveau Technologies, Cevec Pharmaceuticals, Champions Oncology, Chansu Vascular Technologies, Charles River Laboratories, CHARM Therapeutics, Checkmate Pharmaceuticals, Chemify, ChemoCentryx, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Children's Medical Research Institute, Chimeric Therapeutics, Chimeron Bio, Cholesgen, Chroma Medicine, CiMaas, CIMAB SA, Cimeio Therapeutics, Circassia, Citius Pharmaceuticals, City of Hope, Clavius Pharmaceuticals, Clearmind Medicine, Clearside Biomedical, Cleveland Clinic, Clover Biopharmaceuticals, Clovis Oncology, Coalition for Epidemic Preparedness Innovations, Cochlear, Cocoon Biotech, Code Biotherapeutics, Codexis, Codiak BioSciences, Coeptis Pharmaceuticals, Coeptis Therapeutics, CohBar, Coherus Biosciences, CoImmune, Cold Genesys, Collplant, Columbia University, Combotope Therapeutics, Comera Life Sciences, Complement Pharma, Compugen, Conatus Pharmaceuticals, Confo Therapeutics, Contera Pharma, Context Therapeutics, Contineum Therapeutics, ContraFect, Convelo Therapeutics, COPD Foundation, COUR Pharmaceutical, Coya Therapeutics, Creatus Biosciences, Crescendo Biologics, CRISPR Therapeutics, CrystalGenomics, CSIRO, CSL, CSL Behring, CStone Pharmaceuticals, Cue Biopharma, Cugene, Cullgen, Cullinan Oncology, Curasight, CUREator, CureVac, Curis, Cyclica, Cyclo Therapeutics, CymaBay Therapeutics, Cynata Therapeutics, Cyntar Ventures, Cystic Fibrosis Foundation, Cytiva, Cytocom, CytomX Therapeutics, Cytoo, CYTOVIA Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Dare Bioscience, Dartmouth College, Debiopharm, Decibel Therapeutics, Deep Genomics, Defence Research and Development Canada, Defence Therapeutics, Deinove, Dementia Discovery Fund, Denali Therapeutics, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, Dermelix Biotherapeutics, Dermira, Deverra Therapeutics, Devyser Diagnostics, Dewpoint Therapeutics, DiamiR, Diaprost, Dicerna Pharmaceuticals, Dimerix Biosciences, DiNAQOR, DNA Link, Door Pharmaceuticals, DotBio, Dow AgroSciences, Dr. Reddy's Laboratories, Dragonfly Therapeutics, DS Biopharma, DSM, DualityBio, Duke University, Dunad Therapeutics, Durect, Dyadic International, Dynacure, Dyno Therapeutics, DynPort Vaccine Company, Eagle Pharmaceuticals, EDAP TMS, Edesa Biotech, Editas Medicine, eFFECTOR Therapeutics, Eisai, Eisai S.A.S, Elanco, Elektrofi, Element Biosciences, Eligo Bioscience, Eli Lilly, Elpiscience, Elsie Biotechnologies, Emendo Biotherapeutics, Emergence Therapeutics, Emergent BioSolutions, Emmaus Life Sciences, Emory University, Empirico, Enalare Therapeutics, Enara Bio, Enesi Pharma, enGene, EnGeneIC, Enigma Biomedical, Enteris Biopharma, Enterome Bioscience, Entrada Therapeutics, EnWave, Enzychem Lifesciences, Enzyvant Science, EpicentRx, eQcell, EQRx, Equillium, ERS Genomics, ErVimmune, ESSA Pharma, Eterna Therapeutics, eTheRNA immunotherapies, Eticann S.A.S. Zomac, Eurocine Vaccines, European Biomedical Research Institute of Salerno, Evaxion Biotech, Everads Therapy, Everest Medicines, Evestra, Evofem Biosciences, Evopoint Biosciences, EVOQ Therapeutics, Evotec, Evox Therapeutics, Evozyne, EVQLV, Exacis Biotherapeutics, Exelixis, Exeltis, Exicure, Exopharm, ExpreS2ion Biotechnologies, ExScientia, Eyam Vaccines and Immunotherapeutics, EyeMedics, EyePoint Pharmaceuticals, F-Star, F-Star Therapeutics, Fabric Genomics, Facit, FairJourney Biologics, Fate Therapeutics, Fauna Bio, Felix Biotechnology, Ferring Pharmaceuticals, Fibrogen, FightMND, FivepHusion, FKD Therapies, Flagship Pioneering, Flare Therapeutics, Foresee Pharmaceuticals, Forge Therapeutics, Fortis Therapeutics, Fosun Pharmaceutical, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Frontier Medicines, Fujifilm, FUJIFILM Cellular Dynamics, Fusion Pharmaceuticals, Fuzionaire Radioisotope Technologies, G3 Pharmaceuticals, Gadeta, Galapagos, Galaxy Biotech, Galderma, Galmed Pharmaceuticals, GamaMabs Pharma, Gamida Cell, GammaDelta Therapeutics, GC Pharma, Gedeon Richter, GE Healthcare, GEn1E Lifesciences, GenEdit, Genentech, GenePeeks, Generation Bio, Generex Biotechnology, Genethon, GeneTx Biotherapeutics, Genevant Sciences, Genexine, GenFleet Therapeutics, Genisphere, Genmab, Genocea Biosciences, Genome and Company, Genome Biologics, Genticel, GenVec, Genzyme, Georgetown University, George Washington University, GeoVax, German Cancer Research Center, Gicell, Gilead Sciences, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Global Blood Therapeutics, Global Cancer Technology, Glycotope Biotechnology, Glytherix, Goldfinch Bio, Grail, Graphite Bio, Graviton Bioscience, Greenwich LifeSciences, Gritstone Bio, Grunenthal, GSK, Gurnet Point Capital, Gyroscope Therapeutics, H3 Biomedicine, Hadassah Medical Center, Haga Teaching Hospital, HanchorBio, Hannover Medical School, Hansa Biopharma, Harbinger Health, Harpoon Therapeutics, Harvard Medical School, HavaH Therapeutics, Healx, Heartseed, Hebrew University of Jerusalem, Heidelberg Pharma, Helmholtz Zentrum Munchen, Helocyte, Henlius Biotech, Henry Ford Health System, Hepalys Pharma, Heqet Therapeutics, Herantis, HiFiBio, Hikma Pharmaceuticals, Hillstream BioPharma, Histogen, HistoIndex, HitGen, Hoffmann La Roche, Homology Medicines, Hookipa Pharma, Hopstem Biotechnology, Horizon Discovery, Horizon Therapeutics, Hospital for Sick Children, Hoth Therapeutics, HotSpot Therapeutics, Houston Methodist Research Institute, Hubro Therapeutics, Hummingbird Bioscience, Hutchison MediPharma, Hutchmed, I-mab, i2O Therapeutics, IASO Biotherapeutics, Icagen, Icahn School of Medicine at Mount Sinai, Iconic Therapeutics, Iconovo, IDEAYA Biosciences, Idorsia, IFM Therapeutics, IGAN Biosciences, IGNITE Immunotherapy, Iksuda Therapeutics, Iktos, Illumina, ILTOO Pharma, Imbrium Therapeutics, Imcyse, Immatics Biotechnologies, Immix Biopharma, Immuneering, Immune Regulation, Immune System Regulation, ImmuNext, Immunic, Immunicom, ImmunoBiochem, ImmunoCellular Therapeutics, Immunocore, ImmunoGen, Immunome, Immunomedics, Immunomic Therapeutics, Immunovia, Immunscape, Immuron, Immusoft, Immutep, Imperial College London, Imperial Innovations, Imugene, Imunon, IMV, In4Derm, Incyte, Indivior, Infinity Pharmaceuticals, iNGENu, Inhibitor Therapeutics, Inhibrx, Initiator Pharma, Inmagene Biopharmaceuticals, Innate Pharma, Innovasource, Innovate UK, Innovation Pharmaceuticals, Innovent Biologics, Inovio Pharmaceuticals, Inserm Transfert, Insilico Medicine, Insitro, Insmed Inc, InSphero, Inspirna, Institut Curie, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht, Institute of Molecular and Clinical Ophthalmology Basel, Institut Pasteur, Intarcia Therapeutics, Intas Pharmaceuticals, Intec Pharma, IntelGenx, Intellia Therapeutics, Intellikine, IntoCell, Intract Pharma, iNtRON Biotechnology, Inventiva, InxMed, iOncologi, iOnctura, Ionis Pharmaceuticals, IONTAS, Iovance Biotherapeutics, IOVaxis Therapeutics, iProgen Biotech, Ipsen, Ironwood Pharmaceuticals, ISA Pharmaceuticals, Isogenica, Isoprene Pharmaceuticals, iSTAR Medical, Italfarmaco, iTeos Therapeutics, ITM Isotopen Technologien, Iveric Bio, Ivy Brain Tumor Center, Jacobio Pharmaceuticals, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, JFE Engineering, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, Jubilant Therapeutics, Juno Therapeutics, Junshi Biosciences, Jupiter Orphan Therapeutics, Jura Bio, Juventas Therapeutics, JW Therapeutics, KAHR Medical, Kainos Medicines, Kairos Therapeutics, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kallyope, KalVista Pharmaceuticals, Kansas State University, Karolinska Institute, Karveer Meditech, KDAc Therapeutics, Kedalion Therapeutics, Kedrion, Kelonia Therapeutics, Kelun-Biotech Biopharmaceutical, KemPharm, Kezar Life Sciences, Kindeva Drug Delivery, Kindred Bio, Kineta, Kiniksa Pharmaceuticals, KinoPharma, Kite Pharma, Klaria, Krankenhaus Nordwest, KSF Acquisition, KSQ Therapeutics, Kubota Vision, Kukbo, Kymab, Kymera Therapeutics, Kyn Therapeutics, Kyowa Hakko Kirin, Kyowa Hakko Kirin Pharmaceuticals, Kyverna Therapeutics, Laboratoires Thea, Laboratorios Ordesa, La Jolla Institute for Allergy & Immunology, Lantern Pharma, Lantheus Holding, Lantheus Medical Imaging, Lead Discovery Center, Leap Therapeutics, LegoChem Biosciences, LeMaitre Vascular, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, LG Life Sciences, LianBio, Ligand Pharmaceuticals, Light Chain Bioscience, Likarda, Liminal BioSciences, Lineage Cell Therapeutics, Linnaeus Therapeutics, Lipidor, Lipocine, Livzon Mabpharm, LogicBio Therapeutics, Lonza, LSU Health Sciences Center, LTS Lohmann Therapie-Systeme, Lumen Biomedical, Luminary Therapeutics, Luminostics, Lundbeck, Lung Biotechnology, Lupagen, Lupus Therapeutics, Lynkogen, Lysogene, Mabylon, Machavert Pharmaceuticals, Macomics, Macrogenics, Magenta Therapeutics, MAIA Biotechnology, Mainz University Medical Centre, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, Manhattan BioSolutions, MannKind Biopharmaceuticals, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Matinas Biopharma, Maverick Therapeutics, MaveriX Oncology, Max-Planck, Mayo Clinic, Mayo Foundation for Medical Education and Research, MC2 Therapeutics, MD Anderson Cancer Center, Medgenics, Medherant, Medical Technology Enterprise Consortium, Medical University South Carolina, Medice Arzneimittel Pütter, MediciNova, MEDiC Life Sciences, Medidata Solutions, MediGene, MedImmune, Medizone International, MEI Pharma, MeiraGTx, Melior Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Menarini, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Merdury Biopharmaceutical, Mereo BioPharma, Mersana Therapeutics, Merus, Merz, Mesoblast, Mestag Therapeutics, Metagenomi, MetVital, Microbiotica, Micron Biomedical, MicroQuin, Millennium, MiMedx, Mimetas, MiNA Therapeutics, Minneapolis Medical Research Foundation, Mirati Therapeutics, Mirimus, Mirum Pharmaceuticals, Mitokinin, Mitsubishi Chemical, Mitsubishi Tanabe Pharma, MockV Solutions, Moderna, Modulus Discovery, Molecular Partners, Molecular Templates, Moleculin Biotech, Momenta Pharmaceuticals, Monsanto, Monte Rosa Therapeutics, Morphic Therapeutic, MorphoSys, Mor Research Applications, Mosaic ImmunoEngineering, MSD, Multimmune, Multiply Labs, Mundipharma, Murdoch Childrens Research Institute, MustGrow Biologics, MyBiotics Pharma, Mydecine Group, Myeloid Therapeutics, Myeloma Investment Fund, Mymetics, myNEO, Myonexus Therapeutics, Myovant Sciences, Myriad Genetics, Myricx Bio, Nacuity Pharmaceuticals, Nanobiotix, Nanoform, NanoViricides, Nantes University, Nanyang Technological University, Napo EU, Napo Pharmaceuticals, Natera, National Cancer Institute, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institutes of Health, Nationwide Children’s Hospital, Navitor Pharmaceuticals, NBE Therapeutics, NEC, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, Nemysis, NeoImmuneTech, Neomed Institute, Neotope, Neovacs, Nerviano Medical Sciences, Nestle Health Science, NeuBase Therapeutics, NeuExcell, Neumentum, Neuraxpharm, Neurgain Technologies, Neuro3 Therapeutics, Neurocrine Biosciences, NeuroFront, Neurogene, Neurophth Therapeutics, NeuroRx, NeuroSense Therapeutics, Nevada Center For Behavioral Health, Newron Pharmaceuticals, Neximmune, NextCure, Nicox, Nihon Medi-Physics, Nimble Therapeutics, Nimbus Therapeutics, Nippon Shinyaku, NJ Bio, Nkarta Therapeutics, NLS Pharmaceutics, Noile-Immune Biotech, Nordic Nanovector, North Carolina State University, Northwestern University, Novaremed, Novartis, Novellus Therapeutics, Novocure, Novo Nordisk, Noxxon Pharma, Nrgene, Nuance Pharma, Nuevolution, Nuformix, Numab, Nurix Therapeutics, Nutriband, Nuvectis Pharma, Nuvothera, NYU Grossman School of Medicine for Preclinical and Clinical Research, NYU Langone Medical Center, Obsidian Therapeutics, Ocular Therapeutics, Ohara Pharma, Ohio State Innovation Foundation, Ohr Pharmaceuticals, OKYO Pharma, Olema Oncology, OliX Pharmaceuticals, Omega Therapeutics, Ona Therapeutics, OncoArendi Therapeutics, Oncoceutics, Oncodesign, OncoHost, OncoImmune, Oncology Venture, OncoMyx Therapeutics, OncoSec Medical, OncoVent, Oncovir, OnDosis, ONK Therapeutics, OnKure, Ono Pharmaceutical, Onward Therapeutics, Ophthotech, OPKO Health, Opsis Therapeutics, OptiBiotix, Optieum Biotechnologies, Oraxion Therapeutics, Orbis, Orbit Biomedical, Orchard Therapeutics, Oregon Health Sciences University, Orexo, Organon, Orient EuroPharma, Orion, Orion Biotechnology, OSE Immunotherapeutics, Ossianix, Otsuka, Ovensa, Ovid Therapeutics, Oxford BioMedica, Oxford Biomedica Solutions, Oxford BioTherapeutics, Oxford Genetics, Oxford Nanopore Technologies, Oxurion, Oyster Point Pharma, Pairwise Plants, Panbela Therapeutics, Pandion Therapeutics, Pantherna Therapeutics, Papyrus Therapeutics, Paragon Genomics, Pascal Biosciences, Passage Bio, Path BioAnalytics, Pathogen and Microbiome Institute, PDC*line Pharma, PEAR Therapeutics, Pediatric Brain Tumor Consortium, PellePharm, PeptiDream, PeptiMimesis, Personalis, PersonGen BioTherapeutics, Pfenex, Pfizer, Pfizer Consumer Health, PharmaEngine, PharmaIN, PharmaJet, PharmaTher, Pharming Group, PHAXIAM Therapeutics, Phenomic AI, Pherin Pharmaceuticals, Philogen, Phio Pharmaceuticals, Phost’in Therapeutics, PhysIQ, Pieris Pharmaceuticals, Pierre Fabre, Pionyr Immunotherapeutics, Piqur Therapeutics, Plexium, Plus Therapeutics, Polyphor, Portage Biotech, Poseida Therapeutics, Praxis Precision Medicines, Precision BioSciences, Prellis Biologics, Prelude Therapeutics, Presage Biosciences, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, Prime Therapeutics, ProfoundBio, Progenity, Prokarium, Protagonist Therapeutics, Proteomics International, Proteovant Therapeutics, Prothena, Provention Bio, Providence Therapeutics, pSivida, Psycheceutical Bioscience, Pulmatrix, Puma Biotechnology, Purdue Pharma, Purespring Therapeutics, PureTech Health, Puridify, Purple Biotech, PvP Biologics, Q32 Bio, Q BioMed, QBiotics, Qiagen, Qualigen, Quantum Leap Health Care Collaborative, Quartet Medicine, Quebec Consortium for Drug Discovery, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Quell Therapeutics, Quoin Pharmaceuticals, Quotient Clinical, Quris-AI, R-Pharm, Race Oncology, Radiance Biopharma, Radiopharm Theranostics, Radius Health, Rafael Pharmaceuticals, Ragon Institute, Rallybio, Rani Therapeutics, RayzeBio, Recce Pharmaceuticals, Recludix Pharma, ReCode Therapeutics, Recursion, RedHill Biopharma, Redx Pharma, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Regional Cancer Institute of Montpellier, Regor Therapeutics, Regranion, Regulus Therapeutics, Relay Therapeutics, Relief Therapeutics, Remedium Bio, Remix Therapeutics, ReNeuron, Repare Therapeutics, Replicel Life Sciences, Reproductive Medicine Associates of New York, RespireRx Pharmaceuticals, Resverlogix, Retrophin, ReveraGen BioPharma, ReviR Therapeutics, ReVision Optics, Revitope Oncology, ReviveMed, Revive Therapeutics, RevolKa, RevoluGen, Revolution Medicines, Rexahn Pharmaceuticals, Rgenta Therapeutics, Rheos Medicines, Ribometrix, RIKEN Center for Integrative Medical Sciences, Riparian Pharmaceuticals, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Molecular Systems, Rocket Pharmaceuticals, Rockwell Medical, Rodin Therapeutics, Roivant Sciences, Rona Therapeutics, Roswell Park Cancer Institute, RQ Biotechnology, RS BioTherapeutics, RubrYc Therapeutics, Rumpus Therapeutics, RXi Pharmaceuticals, Ryvu Therapeutics, SAB Biotherapeutics, Sairopa, Samabriva, SAMIL Pharm, Samsung Bioepis, Samyang Biopharmaceuticals, SanegeneBio, Sangamo Therapeutics, Saniona, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Sanofi US Services, San Raffaele Scientific Institute, Santen Pharmaceutical, Santhera Pharmaceuticals, Sant Joan de Déu-Barcelona Children’s Hospital, Sarah Cannon Research Institute, Sarepta Therapeutics, Schrodinger, SciClone Pharmaceuticals, SciNeuro Pharmaceuticals, Scipher Medicine, Scorpion Therapeutics, Scribe Therapeutics, Scripps Research Institute, Scynexis, Seagen, Seattle Genetics, Secarna Pharmaceuticals, Second Genome, Selecta Biosciences, SemaThera, Senda Biosciences, SEngine Precision Medicine, Senju Pharmaceutical, Sensorion, Senti Biosciences, Sentinel Oncology, Seres Therapeutics, Sernova, Serum Institute of India, Seven and Eight Biopharmaceuticals, Shattuck Labs, Shenzhen Chipscreen Biosciences, Shenzhen Hepalink Pharmaceutical, Shionogi, Shionogi Pharma, Shoreline Biosciences, Siamab Therapeutics, Silence Therapeutics, Silk Road Therapeutics, Silo Pharma, Simcha Therapeutics, Singular Genomics Systems, SiO2 Medical Products, Sirenas, Sirtex Medical, SiSaf, SK Biopharmaceuticals, Skye Bioscience, Skyhawk Therapeutics, Sofregen Medical, Solid Biosciences, Soligenix, Sonnet BioTherapeutics, Sonoma BioTherapeutics, Sorrento Therapeutics, Sosei, Sosei Heptares, SOTIO, Spark Therapeutics, Spencer Health Solutions, Spherix, Sphingotec, SpineThera, SpliceBio, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, STADA Arzneimittel, Stahl, Stallargenes, Stanford University, Starpharma, Staten Biotechnology, Stealth BioTherapeutics, Stemline Therapeutics, StemoniX, St George Street Capital, Stora Enso, Strand Therapeutics, StrideBio, Stuart Therapeutics, Sucampo Pharmaceuticals, SUDA Pharmaceuticals, Sumitomo Corporation, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Summit Therapeutics, SunRock Biopharma, Supernus Pharmaceuticals, Surface Oncology, Sutro Biopharma, Suzhou NeuPharma, SwanBio Therapeutics, Swedish Orphan Biovitrum, Syena, Symphogen, Symvivo, Synaffix, Syndax Pharmaceuticals, Synlogic, Synthetic Biologics, Synthetic Genomics, Syros Pharmaceuticals, Tachyon Therapeutics, Taiho, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda Pharmaceutical, Takeda Ventures, Talem Therapeutics, Talix Therapeutics, Tango Therapeutics, TARA Biosystems, Targovax, Tautomer Bioscience, Tavros Therapeutics, Taysha Gene Therapies, TB Alliance, Technology University Dresden, Teijin, TekCyte, Telix Pharmaceuticals, TeneoBio, TeneoOne, Tentarix Biotherapeutics, Tesaro, Tetra Bio-Pharma, Tetra Discovery Partners, Tetragenetics, Teva Pharmaceutical Industries, Texas A&M University, Texcell, TFF Pharmaceuticals, TG Therapeutics, The Parker Institute For Cancer Immunotherapy, Theragnostics, Therapeia, Therapix Bio, Theravance, Theriva Biologics, Thermo Fisher Scientific, Thirona Bio, Thomas Jefferson University, Tiba Biotech, TiGenix, Titan Pharmaceuticals, TiumBio, Tizona Therapeutics, Todos Medical, Tome Biosciences, TONIX Pharmaceuticals, Torii Pharmaceutical, Torque Therapeutics, Toxys, TRACON Pharmaceuticals, Transgene, TransThera, TreeFrog Therapeutics, Trevena, Treventis, TRexBio, Trio Pharmaceuticals, Triphase Accelerator, TriSalus Life Sciences, TRT Innovations, Trutino Biosciences, TScan Therapeutics, Tsinghua University, TTC, Tubulis, Tufts Medical Center, Tufts University, Turnstone Biologics, Twist Bioscience, Tyme Technologies, Tyris Therapeutics, Ubiquigent, Ubix Therapeutics, UCB, UK Cystic Fibrosis Gene Therapy Consortium, Ultragenyx Pharmaceuticals, Umoja Biopharma, Uni-Bio Science, Unilever, UNION Therapeutics, UniQuest, UnitedHealth, United Therapeutics, Universite Laval, University College London, University Gottingen, University of Alberta, University of Bonn, University of British Columbia, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Colorado, University of Connecticut, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Houston, University of Kentucky, University of Lausanne, University of Leipzig, University of Leuven, University of Louisville, University of L’Aquila, University of Maryland Baltimore, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Montreal, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Texas Medical Branch, University of Texas Southwestern Medical Center, University of Tubingen, University of Virginia, University of Washington, University of Wisconsin, University of Wollongong, UroGen Pharma, Urovant Sciences, US Army Medical Research Institute of Chemical Defense, UT Southwestern Medical Center, UWM Research Foundation, Vaccinex, Valens Company, ValenzaBio, Valneva, Valo Therapeutics, VantAI, Variational AI, Vasomune Therapeutics, Vaxart, Vaxcyte, Vaximm, VDM Biochemicals, Vect-Horus, VectivBio, Vectura, Vedanta Biosciences, Vensica Medical, Ventana Medical Systems, Verastem, Verge Genomics, VerImmune, Vernalis, Verrica Pharmaceuticals, Vertex Pharmaceuticals, Verve Therapeutics, Vetophage, Vici Health Sciences, Victoria University, Vifor-Fresenius Medical Care Renal Pharma, Vifor Pharma, ViGeneron, Vipergen, Vir Biotechnology, VistaGen Therapeutics, Visterra, Vitaeris, VitalConnect, Vitalli Bio, Vital Therapies, Vitrisa Therapeutics, Vivace Therapeutics, Vivet Therapeutics, Vividion Therapeutics, vivoPharm, Vivoryon Therapeutics, Voluntis, Vor Biopharma, Voyager Therapeutics, VyGen-Bio, VYNE Therapeutics, Vyriad, Washington University in St Louis, WaVe Lifesciences, WAVE Life Sciences, Weill Cornell Medical College, Weizmann Institute, Western Oncolytics, Westport Bio, WinterLight Labs, Wisconsin Alumni Research Foundation, Wistar Institute, Worldwide Clinical Trials, WuXi Biologics, X-chem, Xencor, Xenetic Biosciences, Xenon Pharmaceuticals, XERIS Pharmaceuticals, Xoma, Xyphos Biosciences, Y-Biologics, Y2X Life Sciences, Yale Cancer Center, Yale University, Yeda Research and Development Company, Yield10 Bioscience, Yissum Research Development, Yonsei University Severance Hospital, YouHealth Eyetech, ZAI Laboratory, Zambon, ZappRx, Zealand Pharma, ZebiAI Therapeutics, Zelira Therapeutics, Zenith Epigenetics, Zentalis Pharmaceuticals, Zenyaku Kogyo, Ziopharm Oncology, Zosano Pharma, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!